Characteristic | |
---|---|
Sex, men:women | 5:7 |
Age, mean ± SD yrs | 53.00 ± 11.69 |
Diagnosis | |
Rheumatoid arthritis | 5 |
Psoriatic arthritis | 5 |
Seronegative arthritis | 1 |
Entero-spondyloarthropathy | 1 |
Disease duration, mean ± SD 101.67 ± 63.40 months (range 23 to 226) | |
Previous therapies*, no. patients | |
Methotrexate | 9 |
Cyclosporine | 6 |
Sulfasalazine | 4 |
Hydroxychloroquine | 4 |
Leflunomide | 3 |
Gold salts | 2 |
Anti-TNF treatment duration, mean ± SD 41.08 ± 33.93 months (range 9 to 104) | |
Type of TNF inhibitor, no. patients | |
Etanercept | 7 |
Adalimumab | 5 |
Concomitant DMARD, no. patients | |
Methotrexate | 3 |
Sulfasalazine | 1 |
↵* Since some patients were treated with more than one agent, the cumulative number exceeds 100%. TNF: tumor necrosis factor; DMARD: disease modifying antirheumatic drug.